EMEA-002961-PIP01-21

Key facts

Active substance
Regdanvimab
Therapeutic area
Infectious diseases
Decision number
P/0234/2021
PIP number
EMEA-002961-PIP01-21
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intravenous use
Contact for public enquiries
Celltrion Healthcare Hungary Kft.

Tel. +82-32-850-5913
E-mail: yumi.kim2@celltrion.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating
Average
3 ratings
1 rating